[go: up one dir, main page]

AU2352201A - Improved lysosomal enzymes and lysosomal enzyme activators - Google Patents

Improved lysosomal enzymes and lysosomal enzyme activators

Info

Publication number
AU2352201A
AU2352201A AU23522/01A AU2352201A AU2352201A AU 2352201 A AU2352201 A AU 2352201A AU 23522/01 A AU23522/01 A AU 23522/01A AU 2352201 A AU2352201 A AU 2352201A AU 2352201 A AU2352201 A AU 2352201A
Authority
AU
Australia
Prior art keywords
lysosomal
improved
enzyme activators
enzymes
lysosomal enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU23522/01A
Inventor
Torben Halkier
Anne Dam Jensen
Rikke Bolding Jensen
Jens Sigurd Okkels
Hans Thalsgaard Schambye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxygen ApS
Original Assignee
Maxygen ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen ApS filed Critical Maxygen ApS
Publication of AU2352201A publication Critical patent/AU2352201A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102Alpha-glucosidase (3.2.1.20)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022Alpha-galactosidase (3.2.1.22)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01046Galactosylceramidase (3.2.1.46)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01052Beta-N-acetylhexosaminidase (3.2.1.52)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076L-Iduronidase (3.2.1.76)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU23522/01A 1999-12-30 2000-12-29 Improved lysosomal enzymes and lysosomal enzyme activators Abandoned AU2352201A (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
DKPA199901891 1999-12-30
DKPA199901891 1999-12-30
DKPA200000866 2000-06-02
DKPA200000865 2000-06-02
DKPA200000865 2000-06-02
DKPA200000866 2000-06-02
DKPA200001027 2000-06-30
DKPA200001027 2000-06-30
PCT/DK2000/000743 WO2001049830A2 (en) 1999-12-30 2000-12-29 Improved lysosomal enzymes and lysosomal enzyme activators

Publications (1)

Publication Number Publication Date
AU2352201A true AU2352201A (en) 2001-07-16

Family

ID=27439513

Family Applications (1)

Application Number Title Priority Date Filing Date
AU23522/01A Abandoned AU2352201A (en) 1999-12-30 2000-12-29 Improved lysosomal enzymes and lysosomal enzyme activators

Country Status (4)

Country Link
EP (1) EP1246915A2 (en)
AU (1) AU2352201A (en)
IL (1) IL150314A0 (en)
WO (1) WO2001049830A2 (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378506B2 (en) 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US6639050B1 (en) 1997-07-21 2003-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
AU2001253181A1 (en) * 2000-04-06 2001-10-23 Exegenics, Inc. Expression system for efficiently producing clinically effective lysosomal enzymes (glucocerebrosidase)
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7399613B2 (en) 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
CA2462930C (en) 2001-10-10 2012-07-10 Shawn De Frees Remodeling and glycoconjugation of peptides
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7297511B2 (en) 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
CN102212019B (en) 2003-03-14 2015-05-27 蔚所番有限公司 Branched water-soluble polymers and their conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP2055189A1 (en) 2003-04-09 2009-05-06 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7691603B2 (en) 2003-04-09 2010-04-06 Novo Nordisk A/S Intracellular formation of peptide conjugates
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
WO2004103275A2 (en) 2003-05-09 2004-12-02 Neose Technologies, Inc. Compositions and methods for the preparation of human growth hormone glycosylation mutants
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
IL157772A (en) * 2003-09-04 2016-06-30 Bmr Solutions Ltd Compositions comprising an oligopeptide derived from tortoise spleen for use in stimulating mammalian hemopoiesis
US20070254834A1 (en) 2003-11-24 2007-11-01 Defrees Shawn Glycopegylated Erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
CA2552892C (en) 2004-01-08 2014-08-05 Neose Technologies, Inc. O-linked glycosylation of peptides
WO2005069845A2 (en) 2004-01-14 2005-08-04 Ohio University Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
CA2573918A1 (en) 2004-04-19 2005-11-24 Ohio University Cross-linkable glycoproteins and methods of making the same
KR20070008645A (en) 2004-05-04 2007-01-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 O-linked protein glycoforms of polypeptides and methods for their preparation
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
EP3061461A1 (en) 2004-10-29 2016-08-31 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
EP2514757A3 (en) 2005-01-10 2014-03-05 ratiopharm GmbH Glycopegylated granulocyte colony stimulating factor
EP2386571B1 (en) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1888098A2 (en) 2005-05-25 2008-02-20 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
EP2975135A1 (en) 2005-05-25 2016-01-20 Novo Nordisk A/S Glycopegylated factor IX
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
CA2641588C (en) 2006-02-07 2014-06-17 Shire Human Genetic Therapies, Inc. Stabilized compositions of proteins having a free thiol moiety
EP2029740B1 (en) * 2006-05-31 2012-06-20 Genzyme Corporation Use of polysaccharides for promotion of enzymatic activity
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
JP5967861B2 (en) 2007-04-03 2016-08-10 オキシレイン ユーケー リミテッド Glycosylation of molecules
KR20150064246A (en) 2007-04-03 2015-06-10 바이오제너릭스 게엠베하 Methods of treatment using glycopegylated g―csf
JP2010525833A (en) 2007-05-07 2010-07-29 プロタリクス リミテッド Large-scale disposable bioreactor
CN101778859B (en) 2007-06-12 2014-03-26 诺和诺德公司 Improved process for the production of nucleotide sugars
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
KR101582841B1 (en) 2008-02-27 2016-01-11 노보 노르디스크 에이/에스 Conjugated factor viii molecules
CA3120503A1 (en) 2009-07-28 2011-02-10 Takeda Pharmaceutical Company Limited Compositions and methods for treating gaucher disease
DK2483399T3 (en) 2009-09-29 2019-05-13 Univ Gent HYDROLYSIS OF MANNOSE-1-PHOSPHO-6-MANNOSE BINDING TO PHOSPHO-6-MANNOSE
EP2501805B1 (en) 2009-11-19 2019-02-20 Oxyrane UK Limited Yeast strains producing mammalian-like complex n-glycans
EP2595651B1 (en) * 2010-07-19 2017-03-29 Shire Human Genetic Therapies, Inc. Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof
CN103328646B (en) 2010-09-29 2021-06-18 奥克西雷恩英国有限公司 Mannosidase capable of uncapping mannose-1-phosphate-6-mannose linkages and demannosylating phosphorylated N-glycans and a method of promoting mammalian cellular uptake of glycoproteins
SG189110A1 (en) 2010-09-29 2013-05-31 Oxyrane Uk Ltd De-mannosylation of phosphorylated n-glycans
LT2638152T (en) * 2010-11-08 2016-12-12 Amicus Therapeutics, Inc. Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity
MX361231B (en) 2012-03-02 2018-11-30 Shire Human Genetic Therapies Compositions and methods for treating type iii gaucher disease.
EP2825193B1 (en) 2012-03-15 2019-11-13 Oxyrane UK Limited Methods and materials for treatment of pompe's disease
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
JP2022523104A (en) 2019-02-01 2022-04-21 オキシレイン ユーケー リミテッド Glucocerebrosidase polypeptide
IL296696A (en) * 2020-03-29 2022-11-01 Yeda res & development co ltd Variants of beta-glucocerebrosidase for use in treating gaucher disease
CN116322744A (en) * 2020-07-29 2023-06-23 自由行疗法有限公司 Mutant beta-glucocerebrosidase with increased stability

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
EP0401362B1 (en) * 1988-12-23 1996-05-29 Genzyme Corporation Cho cells producing enzymatically active recombinant glucocerebrosidase
US5549892A (en) * 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
AU2752892A (en) * 1991-09-26 1993-04-27 Oklahoma Medical Research Foundation Fusion proteins targeted to lysosomes, for the treatment of aids
EP0675727B1 (en) * 1992-12-10 2002-04-10 Enzon, Inc. Glycolipid enzyme-polymer conjugates
ATE282087T1 (en) * 1995-07-14 2004-11-15 Novozymes As MODIFIED ENZYME WITH LIPOLYTIC ACTIVITY

Also Published As

Publication number Publication date
IL150314A0 (en) 2002-12-01
WO2001049830A2 (en) 2001-07-12
WO2001049830A3 (en) 2002-02-07
WO2001049830A9 (en) 2002-11-07
EP1246915A2 (en) 2002-10-09

Similar Documents

Publication Publication Date Title
AU2352201A (en) Improved lysosomal enzymes and lysosomal enzyme activators
AU2001286636A1 (en) Method for assaying the activity of lysosomal enzymes
GB2364059B (en) Beta-Secretase enzyme compositions and methods
AUPQ801700A0 (en) Enzyme and viral activation
AU1630501A (en) Compositions and methods for detecting protein modification and enzymatic activity
AU1878601A (en) Enzyme
AU2576100A (en) Novel enzyme
AU9374298A (en) Preparation and use of biofilm-degrading, multiple-specificit y, hydrolytic enzyme mixtures
AU2001262702A1 (en) Coenzyme derivatives and enzymes appropriate therefor
AU1122701A (en) Starch branching enzymes
AU6949200A (en) Human hydrolytic enzymes
AU7125700A (en) Enzyme inhibitors
AU2002221966A1 (en) Enzyme with proteolytic activity
AU6500600A (en) Methods and compositions for determining enzymatic activity
AU7127000A (en) Enzyme inhibitors
AU2001237592A1 (en) Enzymes and uses relating thereto
AU2001238407A1 (en) Esterase enzymes having selective activity
DE60033943D1 (en) SWEEP-FREE ENZYMES
GB0318113D0 (en) ›-Secretase enzyme compositions and methods
AU2001280198A1 (en) Airway-specific trypsin-like enzymes and method of using the same
AU2001264245A1 (en) Novel enzyme gene and its expression product
GB9903019D0 (en) Nitroreductase enzymes
AU7127100A (en) Enzyme inhibitors
AU4367900A (en) Carbohydrate-modifying enzymes
AU2001285392A1 (en) Macromolecular enzyme substrates

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase